目的 一项回顾性研究分析接受Tisa-cel治疗的SCT后复发患者的临床资料,来自7个欧洲国家的27个中心参与了试验,并报告了2018年9月1日至2022年1月1日期间接受治疗的患者数据(Ethics Committeeapproval, University of Frankfurtam Main No.: 2...
Richard Godfrey, CEO of BerGenBio, commented:“We are very encouraged by this promising preliminary response and survival data from the combination of bemcentinib and LDAC in this patient population. Effective treatments with meaningful survival benefit...